Month: May 2024

Mount Logan Capital Inc. Announces First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Dividend Reports And Estimates.

Increased Ability’s total assets managed by Mount Logan to $617 million and reinsured an additional $39 million Multi-Year Guaranteed Annuities during the quarter Generated $9.5 million of insurance segment Spread Related Earnings (“SRE”) for the trailing twelve months ended March 31, 2024, demonstrating the earnings power of the insurance segment Strong quarter for the asset management segment with another quarter of record management fees. Fee Related Earnings (“FRE”) for the quarter of $1.6 million, up 15% as compared to first quarter 2023. FRE increases attributable to growth in Assets Under Management (“AUM”) and management fees Declared quarterly distribution of C$0.02 per common share in the second quarter of 2024, the nineteenth consecutive quarter of a shareholder distribution TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — Mount...

Provident Financial Services, Inc. Announces Pricing and Upsizing of Subordinated Notes Offering

Written by Customer Service on May 9, 2024. Posted in Public Companies.

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) — Provident Financial Services, Inc. (NYSE:PFS) (the “Company”), the holding company for Provident Bank (the “Bank”), today announced the pricing of its offering of $225 million of its 9.00% fixed-to-floating rate subordinated notes due 2034 (the “Notes”) in a registered public offering (the “Offering”). The Notes will initially bear interest at 9.00% per annum, with interest payable semiannually in arrears, commencing on the issue date, to, but excluding, May 15, 2029. Commencing May 15, 2029, the interest rate on the Notes will reset quarterly to a floating rate per annum equal to a benchmark rate that is expected to be Three-Month Term SOFR (which is defined in the Notes) plus 476.5 basis points, with interest payable quarterly in arrears. The Company may redeem the Notes, in whole...

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

Written by Customer Service on May 9, 2024. Posted in Public Companies.

30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC. A replay of the event can be found here.The VERSATILE-002 trial is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive HNSCC. Median...

Victoria’s Secret & Co. Provides First Quarter 2024 Preliminary Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Sales, adjusted operating income, adjusted EPS at the high end or above guidance Reaffirms fiscal 2024 sales and adjusted operating income guidance REYNOLDSBURG, Ohio, May 09, 2024 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“Victoria’s Secret” or the “Company”) (NYSE: VSCO) today provided preliminary results for the first quarter 2024 ended May 4, 2024. Net sales, adjusted operating income, and adjusted diluted earnings per share for the first quarter are at or above previously issued guidance as highlighted in the table below. First Quarter 2024 Preliminary Results Guidance Net Sales (3%) to (4%) (4%) to (6%) Adjusted Operating Income $35 – $40 million $10 – $35 million Adjusted Diluted Earnings Per Share $0.07 to $0.12 ($0.15) to $0.10 Chief Executive...

Source Energy Services Reports Q1 2024 Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) — Source Energy Services Ltd. (TSX: SHLE) (“Source” or the “Company”) is pleased to announce its financial results for the three months ended March 31, 2024. Q1 2024 PERFORMANCE HIGHLIGHTS Key achievements for the quarter ended March 31, 2024 include the following:realized sand sales volumes of 874,849 metric tonnes (“MT”) and sand revenue of $133.0 million, an increase of $1.2 million from the first quarter of 2023; generated total revenue of $169.6 million, a $5.8 million increase from the same period last year; realized gross margin of $35.6 million and Adjusted Gross Margin(1) of $43.2 million, increases of 12% and 14%, respectively, when compared to the first quarter of 2023; reported net income of $1.9 million; realized Adjusted EBITDA(1) of $32.0 million, a $4.4 million improvement...

VitalHub Corp. Reports First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

ARR up 21% YoY to $47.8 millionTotal Revenue up 21% to $15.3 millionEBITDA up 56% YoY to $3.1 million TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management’s Discussion and Analysis report for the three ended March 31, 2024, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com. Dan Matlow, CEO of VitalHub, commented on the quarter’s success, stating, “We are thrilled to report that VitalHub has kicked off 2024 with outstanding momentum, achieving a 21% increase in revenue, which rose to $15.3 million, up from $12.6 million in Q1 last year. Our focus on driving operational excellence and expanding our solution...

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

Written by Customer Service on May 9, 2024. Posted in Public Companies.

SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF), which will take place May 8-11 at the Anaheim Majestic Garden Hotel in Anaheim, California. The CIF has recognized NeOnc’s contributions to medical technology by nominating it for the prestigious Breakthrough Medical Technology Achievement Award to be presented by Treasurer Ma. The forum will feature groundbreaking companies from over 15 countries, providing unparalleled access to a network of investors and partners dedicated to fostering innovative...

Savanna Provides Update on Qualifying Transaction

Written by Customer Service on May 9, 2024. Posted in Mergers And Acquisitions.

Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — SAVANNA CAPITAL CORP. (“Savanna” or the “Company”) (TSX-V: SAC.P), a capital pool company as defined under Policy 2.4 – Capital Pool Companies (the “CPC Policy”) of the TSX Venture Exchange (the “Exchange”), provides an update to its press release dated March 4, 2022 and November 9, 2022 (the “Press Releases”) whereby Savanna announced that it had entered into a definitive agreement dated March 1, 2022 (the “Definitive Agreement”) with 1000090242 Ontario Inc., a privately held corporation existing under the laws of the Province of Ontario (“San Luis ON”), relating to the proposed business combination...

Intermap Announces 42% Revenue Growth in the First Quarter

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

Recurring revenue represented 51% of total revenue and 72% of commercial revenue First payments have been received for the Indonesian mapping program Affirming 2024 projections of $16-18 million in revenue with EBITDA margin of approximately 25% DENVER, May 09, 2024 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced 42% revenue growth in the first quarter of 2024. For the period ending March 31, 2024, the Company reported revenue of $1.7 million, compared with $1.2 million for the fourth quarter of 2023. Additionally, deferred revenue increased by $2.6 million, driven primarily by the receipt of initial payments from the Indonesian government. Adjusted for upfront payments, which were invested to...

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update. Recent Corporate UpdatesPhio’s INTASYL compound PH-762 is currently being investigated in an open-label Phase 1b clinical study (NCT 06014086) to evaluate the safety and tolerability of intratumoral PH-762 in cutaneous squamous cell (cSCC), melanoma, or Merkel cell carcinoma. Two patients have already completed treatment. Four sites across the...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals